Safety and efficacy of nesiritide for the treatment of decompensated heart failure

Reviews in Cardiovascular Medicine

Volumn 3, Issue SUPPL. 4, 2002, Pages

  Emerman, Charles L ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

B type natriuretic peptide; Congestive heart failure; Decompensation; Hypotension; Nesiritide; Safety

Indexed keywords

ANTIARRHYTHMIC AGENT; BRAIN NATRIURETIC PEPTIDE; DIURETIC AGENT; DOBUTAMINE; GLYCERYL TRINITRATE; NESIRITIDE; VASOACTIVE AGENT;

ACUTE HEART FAILURE; ARTICLE; CARDIOVASCULAR FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; LUNG WEDGE PRESSURE; MORTALITY; NAUSEA; TREATMENT OUTCOME; VERTIGO; VOMITING;

CLINICAL TRIALS; EMERGENCY TREATMENT; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN;

EID: 0036382029     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Maisel A. B-type natriuretic peptide in the diagnosis and management of congestive heart failure. Cardiol Clin. 2001;19:557-571.
2. Tulevski II, Hirsch A, Sanson BJ, et al. Increased brain natriuretic peptide as a marker for right ventricular dysfunction in acute pulmonary embolism. Thromb Haemost. 2001;86:1193-1196.
3. Bando M, Ishii Y, Sugiyama Y, Kitamura S. Elevated plasma brain natriuretic pepticle levels in chronic respiratory failure with cor pulmonale. Respir Med. 1999;93:507-514.
4. Kazanegra R, Cheng V, Garcia A, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. I Card Fail. 2001; 7:21-29.
5. Harrison A, Morrison LK, Krishnaswamy P, et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med. 2002;39:131-138.
6. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic pepticle infusion in patients with congestive heart failure: a double-blind, placebo-controlled, randomized crossover trial. Circulation. 1996;94:3184-3189.
7. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiriticle, a natriuretic pepticle, in the treatment of decompensated congestive heart failure. Nesiriticle Study Group. N Engl J Med. 2000;343:246-253.
8. Thomas CJ, Head GA, Woods RL. Similar baroreflex bradyeardic actions of atrial natri-uretic pepticle and B and C types of natriuretic pepticles in conscious rats. J Hypertens. 1999; 17:801-806.
9. Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic pepticle in patients with hemodynamically decompensated heart failure. I Card Fail. 1998;4:37-44.
10. Berger A, Horton D, LeJemtel T. Differential effects of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias: the PRECEDENT study. Am Heart J. In press.
11. VMAC Investigators. Intravenous nesiriticle vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531-1540.
12. Burger AJ, Elkayarn U, Neibaur MT, et al. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesirilide therapy, Am Cardiol. 2001;88:35-39.
13. Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541-1547.